Table 1 Baseline characteristics of 260 responders treated with anti-PD-1 therapies from four pivotal phase 2 trials
Characteristics | Patient No. [n (%)] | P | ||||
|---|---|---|---|---|---|---|
Total (Nā=ā260) | AK105ā201 (Nā=ā76) | BGB-A317ā203 (Nā=ā61) | SHR-1210-II-204 (Nā=ā58) | YH-S001-04 (Nā=ā65) | ||
Sex | Ā | Ā | Ā | Ā | Ā | 0.958 |
āMale | 149 (57.3) | 45 (59.2) | 34 (55.7) | 34 (58.6) | 36 (55.4) | Ā |
āFemale | 111 (42.7) | 31 (40.8) | 27 (44.3) | 24 (41.4) | 29 (44.6) | Ā |
Age (years) | Ā | Ā | Ā | Ā | Ā | 0.050 |
ā>60 | 8 (3.1) | 2 (2.6) | 5 (8.2) | 1 (1.7) | 0 (0.0) | Ā |
āā¤60 | 252 (96.9) | 74 (97.4) | 56 (91.8) | 57 (98.3) | 65 (100.0) | Ā |
Ethnicity | Ā | Ā | Ā | Ā | Ā | 0.576 |
āHan | 254 (97.7) | 74 (97.4) | 61 (100.0) | 56 (96.6) | 63 (96.9) | Ā |
āOthers | 6 (2.3) | 2 (2.6) | 0 (0.0) | 2 (3.4) | 2 (3.1) | Ā |
Histology | Ā | Ā | Ā | Ā | Ā | 0.174 |
āLR | 14 (5.4) | 3 (3.9) | 2 (3.3) | 4 (6.9) | 5 (7.7) | Ā |
āNS | 165 (63.4) | 55 (72.4) | 40 (65.6) | 32 (55.2) | 38 (58.4) | Ā |
āMC | 54 (20.8) | 16 (21.1) | 13 (21.3) | 10 (17.2) | 15 (23.1) | Ā |
āLD | 1 (0.4) | 0 (0.0) | 0 (0.0) | 1 (1.7) | 0 (0.0) | Ā |
āMissing | 26 (10.0) | 2 (2.6) | 6 (9.8) | 11 (19.0) | 7 (10.8) | Ā |
Stage | Ā | Ā | Ā | Ā | Ā | 0.613 |
āI | 2 (0.8) | 1 (1.3) | 1 (1.6) | 0 (0.0) | 0 (0.0) | Ā |
āII | 46 (17.7) | 13 (17.1) | 12 (19.7) | 9 (15.5) | 12 (18.5) | Ā |
āIII | 53 (20.4) | 10 (13.2) | 12 (19.7) | 13 (22.4) | 18 (27.7) | Ā |
āIV | 159 (61.1) | 52 (68.4) | 36 (59.0) | 36 (62.1) | 35 (53.8) | Ā |
ECOG PS | Ā | Ā | Ā | Ā | Ā | 0.054 |
ā0 | 172 (66.2) | 56 (73.7) | 41 (67.2) | 30 (51.7) | 45 (69.2) | Ā |
ā1 | 88 (33.8) | 20 (26.3) | 20 (32.8) | 28 (48.3) | 20 (30.8) | Ā |
B symptoms | Ā | Ā | Ā | Ā | Ā | 0.020 |
āYes | 85 (32.7) | 31 (40.8) | 22 (36.1) | 20 (34.5) | 12 (18.5) | Ā |
āNo | 169 (65.0) | 45 (59.2) | 39 (63.9) | 36 (62.1) | 49 (75.3) | Ā |
āMissing | 6 (2.3) | 0 (0.0) | 0 (0.0) | 2 (3.4) | 4 (6.2) | Ā |
Bulky disease | Ā | Ā | Ā | Ā | Ā | 0.007 |
āYes | 17 (6.5) | 0 (0.0) | 7 (11.5) | 2 (3.4) | 8 (12.3) | Ā |
āNo | 243 (93.5) | 76 (100.0) | 54 (88.5) | 56 (96.6) | 57 (87.7) | Ā |
Elevated LDH | Ā | Ā | Ā | Ā | Ā | <0.001 |
āYes | 70 (26.9) | 27 (35.5) | 20 (32.8) | 17 (29.3) | 6 (9.2) | Ā |
āNo | 150 (57.7) | 49 (64.5) | 41 (67.2) | 41 (70.7) | 19 (29.2) | Ā |
āMissing | 40 (15.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 40 (61.5) | Ā |
Refractory disease | Ā | Ā | Ā | Ā | Ā | <0.001 |
āYes | 184 (70.8) | 74 (97.4) | 20 (32.8) | 49 (84.5) | 41 (63.1) | Ā |
āNo | 76 (29.2) | 2 (2.6) | 41 (67.2) | 9 (15.5) | 24 (36.9) | Ā |
Prior lines of CT | Ā | Ā | Ā | Ā | Ā | 0.581 |
ā2 | 119 (45.8) | 37 (48.7) | 24 (39.3) | 21 (36.2) | 37 (56.9) | Ā |
ā3 | 64 (24.6) | 19 (25.0) | 15 (24.6) | 16 (27.6) | 14 (21.5) | Ā |
ā4 | 32 (12.3) | 10 (13.2) | 8 (13.1) | 7 (12.1) | 7 (10.8) | Ā |
ā5 | 25 (9.6) | 7 (9.2) | 7 (11.5) | 6 (10.3) | 5 (7.7) | Ā |
āā„6 | 20 (7.7) | 3 (3.9) | 7 (11.5) | 8 (13.8) | 2 (3.1) | Ā |
Prior RT | Ā | Ā | Ā | Ā | Ā | <0.001 |
āYes | 79 (30.4) | 22 (28.9) | 12 (19.7) | 30 (51.7) | 15 (23.1) | Ā |
āNo | 178 (68.4) | 54 (71.1) | 49 (80.3) | 28 (48.3) | 47 (72.3) | Ā |
āMissing | 3 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.6) | Ā |
Prior BV | Ā | Ā | Ā | Ā | Ā | 0.065 |
āYes | 9 (3.5) | 0 (0.0) | 4 (6.6) | 4 (6.9) | 1 (1.5) | Ā |
āNo | 251 (96.5) | 76 (100.0) | 57 (93.4) | 54 (93.1) | 64 (98.5) | Ā |
Prior ASCT | Ā | Ā | Ā | Ā | Ā | 0.849 |
āYes | 45 (17.3) | 13 (17.1) | 12 (19.7) | 8 (13.8) | 12 (18.5) | Ā |
āNo | 215 (82.7) | 63 (82.9) | 49 (80.3) | 50 (86.2) | 53 (81.5) | Ā |
